Information  X 
Enter a valid email address

AstraZeneca PLC (AZN)

  Print      Mail a friend       Annual reports

Friday 03 February, 2012

AstraZeneca PLC

Holding(s) in Company

RNS Number : 7967W
AstraZeneca PLC
03 February 2012
 



Disclosure and Transparency Rule 5.8.12

Notification of major interest in shares

 

On 2 February 2012, Investor AB notified the Company that, on 1 February 2012, its interest in the US$0.25 ordinary shares of the Company (the "Shares") had gone above a whole percentage point threshold to 4.02%.

 

The number of Shares, and voting rights, held by Investor AB remains unchanged at 51,587,810 and the increase in the percentage is due to the decrease in the number of Shares in issue as notified by the Company in its monthly voting rights and capital disclosure on 1 February 2012.

 

The full notification from Investor AB is set out below.

 

A C N Kemp

Company Secretary

3 February 2012

 

 

1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:

AstraZeneca PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights


An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached


An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments


An event changing the breakdown of voting rights


Other (please specify):

A change in the total voting rights notified by AstraZeneca PLC on 1 February 2012

P

3. Full name of person(s) subject to the
notification obligation:

Investor AB

4. Full name of shareholder(s)
 (if different from 3.):

N/A

5. Date of the transaction and date on
which the threshold is crossed or
reached:

1 February 2012

6. Date on which issuer notified:

2 February 2012

7. Threshold(s) that is/are crossed or
reached:

Holding increased to above 4%, from above 3%

 

8. Notified details:

A: Voting rights attached to shares

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights

Direct

Direct

Indirect

Direct

Indirect

Ordinary Shares of $0.25 each

51,587,810

51,587,810

51,587,810

51,587,810

N/A

4.02%

N/A

ISIN - GB0009895292


B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date

Exercise/
Conversion Period

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights

N/A

N/A

N/A

N/A

N/A


C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date

Exercise/
Conversion period

Number of voting rights instrument refers to

 

% of voting rights

 

N/A

N/A

N/A

N/A

 

N/A

Nominal

Delta

N/A

N/A


Total (A+B+C)

Number of voting rights

Percentage of voting rights

51,587,810

4.02%

 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:

N/A


Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease
to hold:

N/A

12. Date on which proxy holder will cease to hold
voting rights:

N/A



13. Additional information:

This notification has been prepared using the total voting rights figure of 1,283,229,265 ordinary shares as set out in the public announcement made by AstraZeneca PLC on 1 February 2012

14. Contact name:

Martin Bennett - Assistant Company Secretary

15. Contact telephone number:

020 7604 8157

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLBUGDDSBGBGDX

a d v e r t i s e m e n t